AZD1897 is a PIM1 , PIM2 , and PIM3 inhibitor with IC 50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib ( HY-15431 ). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Pim
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.